Skip to main content
Clinical Trials/NCT06009250
NCT06009250
Not yet recruiting
Not Applicable

Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut

Muhammad Ameen Abdelrady Abdelaziz0 sites200 target enrollmentDecember 2023
ConditionsCKDNAFLD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
CKD
Sponsor
Muhammad Ameen Abdelrady Abdelaziz
Enrollment
200
Primary Endpoint
abdominal ultrasound
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this observational study is to detect the prevalence of NAFLD in CKD patients

The main question[s] it aims to answer are:

  • [question 1] prevalence of NAFLD in CKD patients.
  • [question 2] the relationship between NAFLD and CKD.

Detailed Description

The goal of this observational study is to detect the prevalence of NAFLD in CKD patients The main question\[s\] it aims to answer are: * \[question 1\] prevalence of NAFLD in CKD patients. * \[question 2\] the relationship between NAFLD and CKD.

Registry
clinicaltrials.gov
Start Date
December 2023
End Date
December 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Muhammad Ameen Abdelrady Abdelaziz
Responsible Party
Sponsor Investigator
Principal Investigator

Muhammad Ameen Abdelrady Abdelaziz

Internal Medicine Resident

Assiut University

Eligibility Criteria

Inclusion Criteria

  • CKD patients

Exclusion Criteria

  • HCV and HBV Positive patients
  • Alcoholics
  • patient on Hemodialysis
  • patients with wilson disease
  • patients with alpha one antitrypsin deficiency

Outcomes

Primary Outcomes

abdominal ultrasound

Time Frame: 1 year

assessment of Liver regarding fatty liver disease by Ultrasound.

Complete Blood Picture (WBCs, HB, Patelets

Time Frame: 1 year

total leucocytic count Hemoglobin level and platelet count will be assessed in our patients and will be reported in a table

Fibroscan

Time Frame: 1 year

participants will undergo fibroscanning of the liver to assess NAFLD and results will be reported in a table.

Lipid Profile

Time Frame: 1 year

participants will be assessed regarding Cholesterol level, Triglycerides, HDL and LDL. results will be reported in a table

liver enzymes

Time Frame: 1 year

participants will undergo assessment of liver enzymes (AST and ALT) and results will be reporeted in a table.

BUN, Cr level and estimated GFR

Time Frame: 1 year

participants will be assessed regarding BUN, CR and estimated GFR to confirm and follow up CKD patients involved in the study.

serum Uric Acid

Time Frame: 1 year

serum uric acid will be assessed and reported in our patients

Secondary Outcomes

  • Body Mass Index(1 year)
  • Waist Circumference(1 year)

Similar Trials